The emerging coding frame was applied to the remaining transcripts by a single researcher (MF). Any differences in coding were discussed until a consensus was reached. These codes were applied to several transcripts, and this was then discussed and compared by the research team. These initial codes were then discussed and revised until agreement about their appropriateness was reached by the research team. The first transcript was independently coded by three researchers (MF, XC and BDH). The interviews were audio-recorded, transcribed verbatim and analysed using a constant comparative analysis framework. The interview guide included questions regarding the participant’s general demographics, why they chose to use Implanon NXT, their sources of information, concerns (if any) about Implanon NXT, reason(s) for removal of the device, and their overall experience with the device and its impact on themselves and their relationships. Eligible patients who consented to participate in the study were interviewed for approximately 15–20 minutes by one of two researchers (MF or XC) using a semi-structured interview guide. In total, 66 potential participants were identified and sent a letter of invitation to take part in the research.
The limited literature regarding women’s experiences with long-acting, reversible contraceptive devices in Australia, such as Implanon NXT, include a quantitative retrospective audit of 976 patient charts from two family planning clinics in Queensland, 13 and surveys completed by more than 700 women who had used Implanon NXT from two different studies. 5 Despite the advantages of rapid onset and cessation of action of this implant, it appears that irregular and heavy bleeding are among the main reasons for early removal. Its contraceptive effects cease shortly after removal. 5 Implanon NXT becomes effective immediately after insertion, typically by a GP, into the medial upper arm of female patients. Implanon NXT, introduced in Australia in 2001, is an implantable long-acting, reversible contraceptive rod containing etonogestrel that provides contraception for up to three years. 5 GPs are also more likely to prescribe a new medication at the request of a patient 6 if they believe the patient has a clear understanding of the risks associated with taking the new medication. They are responsible for improving women’s awareness about different contraceptive options, including long-acting, reversible contraceptives, 1–4 and for educating women about the potential side effects of these contraceptive options. General practitioners (GPs) are expected to provide education and advice about contraceptive options to their female patients who are of reproductive age.